Comparative Pharmacology
Head-to-head clinical analysis: EOHILIA versus LIQUID PRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EOHILIA versus LIQUID PRED.
EOHILIA vs LIQUID PRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (cytokines, prostaglandins, leukotrienes).
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
5-60 mg/day orally in divided doses; typical starting dose 5-10 mg every 6-12 hours.
None Documented
None Documented
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
2.1–3.5 hours (terminal elimination half-life; shorter half-life in children; prolonged in hepatic impairment).
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Primarily renal: prednisolone is excreted as glucuronide and sulfate conjugates; less than 1% unchanged. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Corticosteroid
Corticosteroid